Share your thoughts, 1 month free Claude Pro on usSee more
WorkDL logo mark

mCLM: A Modular Chemical Language Model that Generates Functional and Makeable Molecules

About

Despite their ability to understand chemical knowledge, large language models (LLMs) remain limited in their capacity to propose novel molecules with desired functions (e.g., drug-like properties). In addition, the molecules that LLMs propose can often be challenging to make, and are almost never compatible with automated synthesis approaches. To better enable the discovery of functional small molecules, LLMs need to learn a new molecular language that is more effective in predicting properties and inherently synced with automated synthesis technology. Current molecule LLMs are limited by representing molecules based on atoms. In this paper, we argue that just like tokenizing texts into meaning-bearing (sub-)word tokens instead of characters, molecules should be tokenized at the level of functional building blocks, i.e., parts of molecules that bring unique functions and serve as effective building blocks for real-world automated laboratory synthesis. This motivates us to propose mCLM, a modular Chemical-Language Model that comprises a bilingual language model that understands both natural language descriptions of functions and molecular blocks. mCLM front-loads synthesizability considerations while improving the predicted functions of molecules in a principled manner. Experiments on FDA-approved drugs showed that mCLM is capable of significantly improving chemical functions. mCLM, with only 3B parameters, also achieves improvements in synthetic accessibility relative to 7 other leading generative AI methods including GPT-5. When tested on 122 out-of-distribution medicines using only building blocks/tokens that are compatible with automated modular synthesis, mCLM outperforms all baselines in property scores and synthetic accessibility. mCLM can also reason on multiple functions and iteratively self-improve to rescue drug candidates that failed late in clinical trials ("fallen angels").

Carl Edwards, Chi Han, Gawon Lee, Thao Nguyen, Sara Szymku\'c, Chetan Kumar Prasad, Bowen Jin, Jiawei Han, Ying Diao, Ge Liu, Hao Peng, Bartosz A. Grzybowski, Martin D. Burke, Heng Ji• 2025

Related benchmarks

TaskDatasetResultRank
Property-Specific Molecule GenerationBBBP
SA Score2.44
9
Property-Specific Molecule GenerationDILI
Synthetic Accessibility (SA)2.38
9
Property-Specific Molecule GenerationPGP
SA Score2.45
9
Molecular Property OptimizationTDC 122 synthesis-guaranteed FDA-approved drugs
AMES44.4
9
Property-Specific Molecule GenerationAMES
Scaffold Ability (SA)2.39
9
Property-Specific Molecule GenerationCYP3A4
SA2.4
9
Property-Specific Molecule GenerationHIA
Scaffold Ability (SA)2.42
9
Molecular OptimizationTherapeutic Data Commons (TDC) top-10 performance
Amlodipine MPO Score0.387
7
Molecule Generation EvaluationFDA drugs and model-generated molecules 200 random samples per model (test)
SA Score2.43
6
Molecule GenerationFDA Drugs
SA Score2.43
3
Showing 10 of 12 rows

Other info

Follow for update